• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretion.

作者信息

Fazio Sergio, Linton MacRae F

出版信息

Circ Res. 2013 Jul 5;113(2):94-6. doi: 10.1161/CIRCRESAHA.113.301832.

DOI:10.1161/CIRCRESAHA.113.301832
PMID:23833288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3953452/
Abstract
摘要

相似文献

1
Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretion.一石二鸟，或许如此：抑制胆固醇酯转运蛋白（CETP）可同时提高高密度脂蛋白水平并促进胰岛素分泌。
Circ Res. 2013 Jul 5;113(2):94-6. doi: 10.1161/CIRCRESAHA.113.301832.
2
Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion.载脂蛋白转移蛋白抑制作用升高高密度脂蛋白对胰岛素分泌的影响。
Circ Res. 2013 Jul 5;113(2):167-75. doi: 10.1161/CIRCRESAHA.113.300689. Epub 2013 May 15.
3
New horizons for cholesterol ester transfer protein inhibitors.胆固醇酯转移蛋白抑制剂的新前景。
Curr Atheroscler Rep. 2012 Feb;14(1):41-8. doi: 10.1007/s11883-011-0217-9.
4
Anacetrapib: hope for CETP inhibitors?阿昔单抗：CETP 抑制剂的希望？
Cardiovasc Ther. 2011 Oct;29(5):327-39. doi: 10.1111/j.1755-5922.2010.00142.x. Epub 2010 Apr 9.
5
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.胆固醇酯转运蛋白调节剂和抑制剂及其在治疗心血管疾病方面的潜力。
Vasc Health Risk Manag. 2012;8:323-31. doi: 10.2147/VHRM.S25238. Epub 2012 May 15.
6
Cholesteryl ester transfer protein (CETP) inhibitors.胆固醇酯转运蛋白（CETP）抑制剂
Curr Top Med Chem. 2009;9(5):419-27. doi: 10.2174/156802609788340823.
7
On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.托彻普的靶标和非靶标药理学：当前的认识及其对结构-活性关系（SAR）、胆固醇酯转移蛋白（CETP）抑制剂的发现和开发的影响。
Drugs. 2012 Mar 5;72(4):491-507. doi: 10.2165/11599310-000000000-00000.
8
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.新型胆固醇酯转运蛋白抑制剂托彻普对高密度脂蛋白胆固醇水平低于平均水平个体的疗效及安全性
J Am Coll Cardiol. 2006 Nov 7;48(9):1774-81. doi: 10.1016/j.jacc.2006.06.067.
9
Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.CETP 抑制剂的未来：药理学视角。
Clin Pharmacokinet. 2013 Aug;52(8):615-26. doi: 10.1007/s40262-013-0071-8.
10
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.阿那曲匹抑制胆固醇酯转运蛋白可降低高密度脂蛋白载脂蛋白A-I和血浆胆固醇酯转运蛋白的分数清除率。
Arterioscler Thromb Vasc Biol. 2016 May;36(5):994-1002. doi: 10.1161/ATVBAHA.115.306680. Epub 2016 Mar 10.

引用本文的文献

1
Association between hs-CRP/HDL with type 2 diabetes mellitus in middle-aged and elderly people: a cross-sectional study from CHARLS.中老年人群中高敏C反应蛋白与高密度脂蛋白的比值与2型糖尿病的关联：基于中国健康与养老追踪调查（CHARLS）的横断面研究
Front Endocrinol (Lausanne). 2025 Mar 7;16:1471292. doi: 10.3389/fendo.2025.1471292. eCollection 2025.
2
Blood lipid profile, HbA1c, fasting glucose, and diabetes: a cohort study and a two-sample Mendelian randomization analysis.血脂谱、HbA1c、空腹血糖和糖尿病：一项队列研究和两样本 Mendelian 随机分析。
J Endocrinol Invest. 2024 Apr;47(4):913-925. doi: 10.1007/s40618-023-02209-x. Epub 2023 Oct 25.
3
Obesity-associated metabolites in relation to type 2 diabetes risk: A prospective nested case-control study of the CARRS cohort.肥胖相关代谢物与 2 型糖尿病风险的关系：CARRS 队列的前瞻性巢式病例对照研究。
Diabetes Obes Metab. 2022 Oct;24(10):2008-2016. doi: 10.1111/dom.14788. Epub 2022 Jul 5.
4
HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review.高密度脂蛋白胆固醇与非心血管疾病：一篇叙述性评论。
Int J Mol Sci. 2021 Apr 27;22(9):4547. doi: 10.3390/ijms22094547.
5
CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet.CETP 抑制可改善高密度脂蛋白功能，但在高脂肪饮食的 CETP 表达转基因小鼠中会导致脂肪肝和胰岛素抵抗。
Diabetes. 2018 Dec;67(12):2494-2506. doi: 10.2337/db18-0474. Epub 2018 Sep 13.
6
The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk.高密度脂蛋白在糖尿病患者及相关心血管风险中的作用和功能。
Lipids Health Dis. 2017 Oct 30;16(1):207. doi: 10.1186/s12944-017-0594-3.
7
Lipotoxicity in the pancreatic beta cell: not just survival and function, but proliferation as well?胰腺β细胞中的脂毒性：不仅仅关乎生存和功能，还涉及增殖吗？
Curr Diab Rep. 2014 Jun;14(6):492. doi: 10.1007/s11892-014-0492-2.

本文引用的文献

1
Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion.载脂蛋白转移蛋白抑制作用升高高密度脂蛋白对胰岛素分泌的影响。
Circ Res. 2013 Jul 5;113(2):167-75. doi: 10.1161/CIRCRESAHA.113.300689. Epub 2013 May 15.
2
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.HPS2-THRIVE 随机安慰剂对照试验纳入 25673 例 ER 烟酸/拉罗匹仑的高危患者：试验设计、预先指定的肌肉和肝脏结局以及停止研究治疗的原因。
Eur Heart J. 2013 May;34(17):1279-91. doi: 10.1093/eurheartj/eht055. Epub 2013 Feb 26.
3
Effects of dalcetrapib in patients with a recent acute coronary syndrome.近期急性冠脉综合征患者应用达塞曲匹的效果。
N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.
4
Rationale for cholesteryl ester transfer protein inhibition.胆固醇酯转移蛋白抑制的理由。
Curr Opin Lipidol. 2012 Aug;23(4):372-6. doi: 10.1097/MOL.0b013e328353ef1d.
5
Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study.苯扎贝特对伴有糖尿病的血脂异常患者脂代谢和糖代谢的影响：J-BENEFIT 研究。
Cardiovasc Diabetol. 2012 Mar 23;11:29. doi: 10.1186/1475-2840-11-29.
6
Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules.由于 ABCA1 的缺失导致胰岛胆固醇积累，从而导致胰岛素颗粒的胞吐作用受损。
Diabetes. 2011 Dec;60(12):3186-96. doi: 10.2337/db11-0081. Epub 2011 Oct 12.
7
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.达塞曲匹在 2 型糖尿病和/或代谢综合征患者，伴高心血管疾病风险中的疗效和安全性。
Diabetes Obes Metab. 2012 Jan;14(1):30-9. doi: 10.1111/j.1463-1326.2011.01485.x. Epub 2011 Nov 21.
8
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.torcetrapib 对 Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events（ILLUMINATE）试验中受试者的血糖、胰岛素和血红蛋白 A1c 的影响。
Circulation. 2011 Aug 2;124(5):555-62. doi: 10.1161/CIRCULATIONAHA.111.018259. Epub 2011 Jul 18.
9
Are statins diabetogenic?他汀类药物会导致糖尿病吗？
Curr Opin Cardiol. 2011 Jul;26(4):342-7. doi: 10.1097/HCO.0b013e3283470359.
10
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.阿托伐他汀治疗新诊断 1 型糖尿病患者后的残余β细胞功能：随机 DIATOR 试验。
PLoS One. 2011 Mar 11;6(3):e17554. doi: 10.1371/journal.pone.0017554.